Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
| • | Annual cash retainers will be paid for service on Board committees in amounts to be determined; and, |
| • | Options awarded will vest in equal quarterly increments over a one-year period from the date of grant. |
In accordance with the Company’s Amended and Restated By-laws, stockholder nominations for directors must be received no later than the close of business on June8, 2018 in order to be considered at the 2018 Annual Meeting. Such proposals must be delivered to the Company’s Controller at 17 State Street – 7th Floor, New York, New York 10004 and must also comply with all other requirements set forth in the Company’s Amended and Restated By-laws and other applicable laws.
| Item 5.02 | Financial Statements and Exhibits. |
Set forth below is a list of the exhibits to this Current Report on Form 8-K.
TYME TECHNOLOGIES, INC. ExhibitEX-99.1 2 d591146dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 TYME TECHNOLOGIES,…To view the full exhibit click here
About Tyme Technologies, Inc. (OTCMKTS:TYMI)
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.
